Dr. Malempati publishes key Rhabdomyosarcoma Study

Congratulations to Dr. Suman Malempati, whose study of rhabdomyosarcoma in children less than a year of age has recently been published in the journal, Cancer.  This study from the Children's Oncology Group underlines the importance of local control in the care of these infant patients.  

Kyla McCullough Gift Fund furthering Research, every day

We extend our heartfelt thanks to the Kyla McCullough Gift Fund who have made a generous gift of a vital instrument to Pediatric Cancer Biology Program laboratories.  This NanoDrop Spectrophotometer (pictured in the left bottom corner) is a special type of instrument uses sparingly small amounts of our experimental samples to measure the concentration of DNA and RNA that the samples contain.  This spectrophotometer will be used by multiple laboratories very often - approximately 7–10 researchers each day. A placard on the instrument reads:
 

Kyla McCullough Gift Fund

Know You’re Loved Always

Kyla was diagnosed with a brain tumor in First Grade and she touched many lives.  Her memory, kindness and strength of spirit live on in the selfless advocacy for new treatments of childhood cancers - the mission of her her parents and the board of the Kyla McCullough Gift Fund.  

  

  

PCB Leader joins Northwest Sarcoma Foundation Board

It is with great appreciation that Pediatric Cancer Biology Program Leader, Dr. Charles Keller, has joined in service to the Board of Director of the Northwest Sarcoma Foundation (NWSF). The NWSF and the PCB Program are strategic partners in an NCI-funded outreach effort funded by the Carolyn Price Walker Act.  Working increasingly in synergy with our clinical care partners in Seattle, we hope to make the most advanced treatments and the best patient support available throughout the Pacific Northwest.     

  

The Fedorov Laboratory

The laboratory of Lev Fedorov investigates the important cross-talk between the Tuberous Sclerosis Complex (TSC) and the mTor pathway.  By focusing on the Ras homolog enriched in brain (Rheb) gene using mouse genetics, important aspects of normal human development, birth defects and tumor predisposition syndromes (phakomatoses) can be understood.  The intersection of these signaling cascades is also important to a number of other pediatric cancer to which targeted therapies are being developed. In addition to this research, Dr. Fedorov directs the OHSU Transgenic Mouse Models Shared Resource.  
  
To contact Dr. Fedorov about his exciting work, email him at fedorovl-at-ohsu.edu .
  
  
 

Knight Seminar Series for Spring 2011

This seminar series is co-sponsored by the Knight Cancer Institute and the Pediatric Cancer Biology Program. 
  

Upcoming Seminar by Dr. Brian Rubin

Brian Rubin, MD, PhD, Associate Professor of Anatomic Pathology and Director of Soft Tissue Pathology at the Cleveland Clinic, Taussig Cancer Institute, will be visiting OHSU on Tuesday, January 18 to give a presentation entitled, “Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumor.” The seminar will take place from 4 to 5 p.m. in OHSU Main Hospital, room 8B60.